[go: up one dir, main page]

WO1998011229A3 - Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof - Google Patents

Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof Download PDF

Info

Publication number
WO1998011229A3
WO1998011229A3 PCT/US1997/015836 US9715836W WO9811229A3 WO 1998011229 A3 WO1998011229 A3 WO 1998011229A3 US 9715836 W US9715836 W US 9715836W WO 9811229 A3 WO9811229 A3 WO 9811229A3
Authority
WO
WIPO (PCT)
Prior art keywords
toxoids
toxins
purification
shiga
tagged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/015836
Other languages
French (fr)
Other versions
WO1998011229A2 (en
Inventor
Alison D O'brien
Clare K Schmitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority to EP97939845A priority Critical patent/EP0929679A2/en
Priority to CA002265887A priority patent/CA2265887A1/en
Priority to AU41845/97A priority patent/AU4184597A/en
Priority to JP10513748A priority patent/JP2001500730A/en
Publication of WO1998011229A2 publication Critical patent/WO1998011229A2/en
Publication of WO1998011229A3 publication Critical patent/WO1998011229A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention describes the isolation and purification of biologically and immunologically active histidine-tagged Shiga toxins (His-tagged), a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how his-tagging greatly simplifies and expedites purifying Shiga toxins, and describes an improved method for such purification. One aspect of the invention is obtaining and using Shiga toxoids that are immunoreactive but not toxic. Another aspect of the invention is obtaining and using fusion proteins of His-tagged Shiga toxins or toxoids. Yet another aspect of the invention is obtaining and using antibodies to His-gagged Shiga toxins, toxoids, or Shiga toxin/toxoid fusion proteins.
PCT/US1997/015836 1996-09-10 1997-09-09 Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof Ceased WO1998011229A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97939845A EP0929679A2 (en) 1996-09-10 1997-09-09 Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
CA002265887A CA2265887A1 (en) 1996-09-10 1997-09-09 Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
AU41845/97A AU4184597A (en) 1996-09-10 1997-09-09 Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
JP10513748A JP2001500730A (en) 1996-09-10 1997-09-09 Histidine-tagged Shiga toxin and toxoid, fusion protein with the toxin and toxoid, and methods for purification and preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2563796P 1996-09-10 1996-09-10
US60/025,637 1996-09-10

Publications (2)

Publication Number Publication Date
WO1998011229A2 WO1998011229A2 (en) 1998-03-19
WO1998011229A3 true WO1998011229A3 (en) 1998-04-16

Family

ID=21827219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015836 Ceased WO1998011229A2 (en) 1996-09-10 1997-09-09 Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof

Country Status (6)

Country Link
EP (1) EP0929679A2 (en)
JP (1) JP2001500730A (en)
AR (1) AR010218A1 (en)
AU (1) AU4184597A (en)
CA (1) CA2265887A1 (en)
WO (1) WO1998011229A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US10815469B2 (en) 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
US11104707B2 (en) 2015-02-05 2021-08-31 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereof
US11225509B2 (en) 2018-04-17 2022-01-18 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds
US11312751B2 (en) 2014-01-27 2022-04-26 Molecular Templates, Inc. MHC class I epitope delivering polypeptides
US11365223B2 (en) 2015-05-30 2022-06-21 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US11389542B1 (en) 2016-12-07 2022-07-19 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11406692B2 (en) 2017-01-25 2022-08-09 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766193B1 (en) 1997-07-18 2001-09-14 Inst Curie CHEMICAL POLYPEPTIDE COMPRISING FRAGMENT B OF TOXIN SHIGA AND PEPTIDES OF THERAPEUTIC INTEREST
GB9715177D0 (en) * 1997-07-21 1997-09-24 Neutec Pharma Plc Medicament
ES2255269T3 (en) * 1998-05-15 2006-06-16 Institut Curie SUBUNITY B OF VEROTOXINE FOR IMMUNIZATION.
EP1057895A1 (en) * 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Fusion protein comprising Shiga toxin 2e B subunit, (vaccine)compositions comprising it, and methods for their production
WO2007098201A2 (en) * 2006-02-16 2007-08-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Shiga toxoid chimeric proteins
JP2009536818A (en) * 2006-04-20 2009-10-22 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Methods and compositions based on Shiga toxic type 1 protein
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
ES2800630T3 (en) * 2013-03-12 2021-01-04 Molecular Templates Inc Cytotoxic proteins comprising cell recognition binding regions and regions of the A subunit of Shiga toxin for the selective elimination of specific cell types
ES2864124T3 (en) * 2014-03-11 2021-10-13 Molecular Templates Inc Proteins comprising binding regions, effector regions of Shiga toxin A subunit, and carboxy-terminal endoplasmic reticulum localization signal motifs
SMT202100379T1 (en) * 2014-03-11 2021-09-14 Molecular Templates Inc Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions capable of specifically binding cd38
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
KR102869667B1 (en) * 2023-01-13 2025-10-16 전북대학교산학협력단 Mass Production Method of Recombinant Stx2e Toxoid and Swine Edema Disease Vaccine Composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012802A1 (en) * 1989-10-31 1996-05-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of c. difficile disease
WO1996030043A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012802A1 (en) * 1989-10-31 1996-05-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of c. difficile disease
WO1996030043A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FRYXELL D. ET AL.: "Genetic construction of a phosphorylation site in ricin A chain: Specific radiolabeling of recombinant proteins for localization and degradation studies.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 210, no. 2, 1995, pages 253 - 259, XP002054492 *
GORDON V.M. ET AL.: "An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for Edema disease of swine.", INFECTION AND IMMUNITY, vol. 60, no. 2, 1992, pages 485 - 490, XP002054488 *
HOCHULI E. ET AL.: "Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent.", BIOTECHNOLOGY, vol. 6, no. 11, 1988, pages 1321 - 1325, XP002054489 *
LI J.: "Bacterial toxins.", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 2, no. 4, 1992, pages 545 - 556, XP000335477 *
LINDGREN S. W. ET AL.: "The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxin of Enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality.", INFECTION AND IMMUNITY, vol. 62, no. 2, 1994, pages 623 - 631, XP002054490 *
TANG D. ET AL.: "Genetic immunization is a simple method for eliciting an immune response.", NATURE, vol. 356, 1992, pages 152 - 154, XP000310569 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166702B1 (en) 1998-07-22 2007-01-23 Osprey Pharmaceuticals, Ltd. Cytotoxic conjugates comprising a chemokine receptor targeting agent
US7192736B2 (en) 1998-07-22 2007-03-20 Osprey Pharmaceuticals, Ltd. Nucleic acid molecules encoding cytotoxic conjugates that contain a chemokine receptor targeting agent
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US11312751B2 (en) 2014-01-27 2022-04-26 Molecular Templates, Inc. MHC class I epitope delivering polypeptides
US12065469B2 (en) 2014-01-27 2024-08-20 Molecular Templates, Inc. De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals
US12037367B2 (en) 2014-01-27 2024-07-16 Molecular Templates, Inc. MHC class I epitope delivering polypeptides
US10815469B2 (en) 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
US11104707B2 (en) 2015-02-05 2021-08-31 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin a subunit effector regions and enriched compositions thereof
US11365223B2 (en) 2015-05-30 2022-06-21 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US11389542B1 (en) 2016-12-07 2022-07-19 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11857628B2 (en) 2016-12-07 2024-01-02 Molecular Templates, Inc. Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US11406692B2 (en) 2017-01-25 2022-08-09 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes
US11225509B2 (en) 2018-04-17 2022-01-18 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A subunit scaffolds

Also Published As

Publication number Publication date
AR010218A1 (en) 2000-06-07
EP0929679A2 (en) 1999-07-21
JP2001500730A (en) 2001-01-23
CA2265887A1 (en) 1998-03-19
AU4184597A (en) 1998-04-02
WO1998011229A2 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
WO1998011229A3 (en) Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
Matsuda et al. Isolation and purification of two antigenically active," complimentary" polypeptide fragments of tetanus neurotoxin
DE69233375T2 (en) FOR A SIGNAL PEPTIDE, A SELECTIVELY INTERCHANGEABLE POLYPEPTIDE, AND A MEMBRANE ANGLE SEQUENCE ENCODING RECOMBINANT DNA
Meyer et al. Pyoverdin‐facilitated iron uptake in Pseudomonas aeruginosa: immunological characterization of the ferripyoverdin receptor
GR3029477T3 (en) Vaccine against gram-negative bacterial infections
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
ATE359370T1 (en) HETEROLOGUE ANTIGENS IN STRAINS FOR LIVE CELL VACCINATION
CA2127362A1 (en) Expression and Purification of Recombinant Soluble Tissue Factor
EP0749321A4 (en) Active immunization using a siderophore receptor protein
IL128014A (en) Method of producing active immunity with vaccine conjugate, a vaccine preparation useful for the production of said vaccine conjugate and a process for the manufacture of said vaccine
WO1991015505A1 (en) Purification of a pertussis outer membrane protein
Matsuda et al. Antigenic substructure of tetanus neurotoxin
CA1123734A (en) E. coli enterotoxin vaccine for veterinary and human use
Ohta et al. Characterization of a cell-surface protein antigen of hydrophilic Streptococcus mutans strain GS-5
DE69131624D1 (en) PEPTIDE COMPOSITION FROM PSEUDOMONAS AND METHOD TO MAKE THEM
CA2316411A1 (en) Humanized monoclonal antibodies that protect against shiga toxin induced disease
AU1781495A (en) Vaccine for nontypable haemophilus influenzae strain
EP1338607A3 (en) Antigenic iron repressible proteins from n. meningitidis related to the heolysin family of toxins
AU601415B2 (en) A process for the purification, solubilization and/or detoxification of protein antigens of bacteria of the bordetella genus using a carbonate buffer and an acellular anti-whooping cough vaccine
Gyka et al. Crosslinkage of antibodies to staphylococcal protein A matrices
Scott et al. Affinity chromatography purification of Clostridium perfringens enterotoxin
ES2081864T3 (en) METHOD TO PURIFY A PROTEIN FROM THE OUTER MEMBRANE OF HAEMOPHILUS INFLUENZAE.
EP0087735A2 (en) Recombinant DNA, microorganism transformed therewith and their use
GB9201013D0 (en) Vaccines
SE8403929L (en) RECOMBINANT DNA MOLECULE, TRANSFORMED MICROORGANISMS AND PROCEDURE FOR PENICILLIN V-AMIDAS PREPARATION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2265887

Country of ref document: CA

Ref country code: CA

Ref document number: 2265887

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 513748

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997939845

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997939845

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997939845

Country of ref document: EP